检索结果-南通市图书馆

Add-on plasmonic patch as a universal fluorescence enhancer

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Light(Science & Applications) 2018年第1期7卷 795-807页

作者： Jingyi Luan Jeremiah J.Morrissey Zheyu Wang Hamed Gholami Derami Keng-Ku Liu Sisi Cao Qisheng Jiang Congzhou Wang Evan D.Kharasch rajesh r.naik Srikanth Singamaneni Department of Mechanical Engineering and Materials Science Institute of Materials Science and EngineeringWashington University in St.LouisSt LouisMO 63130USA Department of Anesthesiology Washington University in St.LouisSt.LouisMO 63110USA Siteman Cancer Center Washington University in St.LouisSt.LouisMO 63110USA Department of Biochemistry and Molecular Biophysics Washington University in St.LouisSt.LouisMO 63110USA The Center for Clinical Pharmacology St.Louis College of Pharmacy and Washington University School of MedicineSt.LouisMOUSA 711th Human Performance Wing Air Force Research LaboratoryWright-Patterson Air Force BaseDaytonOH 45433USA

Fluorescence-based techniques are the cornerstone of modern biomedical optics,with applications ranging from bioimaging at various scales(organelle to organism)to detection and quantification of a wide variety of biological species of ***,the weakness of the fluorescence signal remains a persistent challenge in meeting the ever-increasing demand to image,detect,and quantify biological species with low ***,we report a simple and universal method based on a flexible and conformal elastomeric film with adsorbed plasmonic nanostructures,which we term a“plasmonic patch,”that provides large(up to 100-fold)and uniform fluorescence enhancement on a variety of surfaces through simple transfer of the plasmonic patch to the *** demonstrate the applications of the plasmonic patch in improving the sensitivity and limit of detection(by more than 100 times)of fluorescence-based immunoassays implemented in microtiter plates and in microarray *** novel fluorescence enhancement approach presented here represents a disease,biomarker,and application agnostic ubiquitously applicable fundamental and enabling technology to immediately improve the sensitivity of existing analytical methodologies in an easy-to-handle and cost-effective manner,without changing the original procedures of the existing techniques.

关键词： patch plasmon corners

In-silico and in-vitro evaluation of docetaxel and berberine as potential p53 modulating apoptotic inducers in oral squamous cell carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Pacific Journal of Tropical Biomedicine 2022年第12期12卷 530-540页

作者： Smrutipragnya Samal rajesh Kumar Meher Debasmita Dubey Showkat Ahmad Mir Binata Nayak Mahesh Chandra Sahu Pradeep Kumar.naik Goutam rath Santosh Kumar Swain Department of Otorhinolaryngology and Head and Neck Surgery IMS and SUM HospitalSiksha‘O’Anusandhan Deemed to be UniversityK8Kalinga NagarBhubaneswar-751003OdishaIndia Centre of Excellence in Natural Products and Therapeutics Department of Biotechnology and BioinformaticsSambalpur UniversityJyotiviharBurlaSambalpurOdishaIndia Medical research Laboratory IMS and SUM HospitalSiksha‘O’Anusandhan Deemed to be UniversityK8Kalinga NagarBhubaneswar-751003OdishaIndia School of Life Sciences Sambalpur UnivesityJyotiviharBurlaSambalpurOdishaIndia ICMr-regional Medical research Centre ChandrasekharpurBhubaneswar-751023India School of Pharmaceutical Sciences Siksha‘O’Anusandhan Deemed to be UniversityBhubaneswar-751030India

Objective:To investigate the interaction of p53 with docetaxel and berberine and their anticancer activities against oral squamous cell ***:The interaction between p53 with docetaxel and berberine was investigated and their mechanisms of action against oral squamous cell carcinoma were *** studies were performed to determine any toxic impact of the drugs on the vital organs of tested ***:In silico results revealed the molecular interaction of docetaxel and berberine with p53 and the molecules were found to be potential p53 *** and berberine inhibited the proliferation of cancer cells in a concentration-dependent *** cytometry analysis revealed that docetaxel and berberine at IC50 concentrations upregulated the expression of p53 in oral squamous cell carcinoma cells,thus triggering apoptotic cell *** addition,no toxicity was observed in the liver and kidney tissues of mice after docetaxel and berberine ***:Docetaxel and berberine significantly suppressed the proliferation of oral cancer cells by activating p53 expression and causing apoptotic cell *** compounds can be potential agents for the treatment of oral cancer,with little to no toxicity at the tissue level.

关键词： Docetaxel Berberine PC-3 OVCAr-3 OSCC SCC-29B p53 Anticancer Apoptosis

Safety and Efficacy of Neoadjuvant DOF [Docetaxel, Oxaliplatin, 5-Fluorouracil] Chemotherapy regimen in Patients with Locally Advanced Gastric and Gastro-Esophageal Junction Cancers: A Single Center Experience from India

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2020年第5期11卷 237-250页

作者： Vishal Kulkarni Satheesh Chiradoni Thungappa Shekhar Patil Vinu Sarathy Kiran Pura Krishnamurthy rajesh Kumar radheshyam naik Department of Medical Oncology Health Care Global Enterprises Ltd. Bangalore India

Background:?The role of chemotherapy in Gastric Cancer is constantly evolving?with various neoadjuvant and adjuvant strategies. Several chemotherapeutic agents are used in the treatment of locally advanced gastric cancer (LAGC) namely Platinum based compounds (Cisplatin, Oxaliplatin), Fluoropyrimidines like 5-Flurouracil [(5-FU), Capecitabine)], Taxanes (Docetaxel) and Anthracyclines (Epirubicin). Various doublet and triplet combination chemotherapy regimens have been used for neo-adjuvant chemotherapy (NACT) in LAGCs. In this study we evaluated the safety and efficacy of docetaxel based triplet regimen DOF [Docetaxel, Oxaliplatin, 5-Fluorouracil] in LAGC. Material and methods:?50 Newly diagnosed patients of Locally Advanced Gastric Cancer (stage II or III) deemed fit to receive chemotherapy were included in our study. After 3 cycles of neoadjuvant chemotherapy, patients were assessed based on radiological and pathological response.?results: 50 Patients were included in our study of which majority were male (32), median age at presentation was 55 years and 24 patients presented with a history of gastrointestinal reflux disease (GErD). The most common hematological toxicities observed in our study were anemia (61.2%), neutropenia (42.6%, febrile neutropenia constituted 6%) and thrombocytopenia (13.2%). The most common gastro-intestinal [GI] toxicities observed in our study included nausea (69.2%), vomiting (31.2%), diarrhea (34%), oral mucositis (14%) and constipation (6.6%). We found that safety profile of DOF regimen was favorable with majority of patients tolerating the regimen well. The Overall response rate (68%), Disease Control rate (96%) and resectability rate (80%) were higher compared to western studies. Pathological Cr (17.5%), ypN0?disease status (42.5%) and nodal down staging (52%), all showed positive correlations with survival outcomes. Conclusion:?DOF regimen is an effective and feasible option for neoadjuvant treatment of LAGC in an Indian population

关键词： Locally Advanced Gastric Cancer (LAGC) Neoadjuvant Chemotherapy DOF (Docetaxel Oxaliplatin 5-Fluorouracil) Safety Toxicity

Correlation of Programmed Death Ligand-1 (PD-L1) Expression with Clinicopathological Features in Non-Small Cell Lung Carcinoma: Experience from a Tertiary Cancer Care Center in India

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2020年第3期11卷 172-187页

作者： Hafsa Saif K. S. rajesh Kumar Suhail Sayeed Mufti ritesh Giri V. Hrishi Vinu Sarathy Veena ramaswamy Diganta Hazarika radheshyam naik Department of Pathology HealthCare Global (HCG) Hospital Bengaluru India Department of Translational Medicine & Therapeutics Health Care Global (HCG) Hospital Bengaluru India Department of Clinical Pharmacy Health Care Global (HCG) Hospital Bengaluru India Department of Medical Oncology Health Care Global (HCG) Hospital Bengaluru India Histopathology Department Health Care Global (HCG) Hospital Bengaluru India Department of Medical Oncology Hematology and BMT Bengaluru India

Background:?According to the GLOBOCAN 2018 report, the estimated incidence of lung cancer in India was 67,795 in both sexes. The treatment of advanced Non-small cell lung cancer (NSCLC) saw a major paradigm shift with recent advances in molecular-targeted therapy. Immune checkpoint blockade therapy is one such novel strategy with promising clinical benefits in advanced NSCLC. Programmed cell death receptor-1/Programmed cell death ligand-1 (PD-1/PD-L1) pathway is one such checkpoint and has thus become the current area of interest in the treatment of lung carcinoma. The PD-1/?PD-L1 pathway is under active investigation as it represents a promising therapeutic target in NSCLC. The expression of PD-L1 in tumor cells has been suggested as a predictive marker of the clinical response to PD-1/?PD-L1-targeted therapy. Methods: This study was carried out at the Department of Pathology, Health Care Global Specialty Hospital, Bangalore from May 2018 to May 2019. In this study, we analyzed pattern of PD-L1 expression by immunohistochemistry testing using our own Laboratory Developed Test (LDT) in NSCLC patients. results:?Our study group comprised 50 patients of NSCLC. Among our study population, 40% of the patients exhibited PD-L1 immunopositivity (≥1%) with 28% of them having any expression (TPS 1% - 49%) and 12% of them having a high expression (TPS ≥ 50%) of PD-L1. Majority of them exhibited adenocarcinoma type of NSCLC under which the solid subtype showed a direct correlation with PD-L1 positivity (p-value: 0.004) with a poorly differentiated tumor histology being common in our population in relation to PD-L1 positivity (p-value: 0.043). PD-L1 expression did not correlate with age, gender, smoking status or clinical stage in our study. No association was found between tumor histology (SCC or AC) and driver mutation status with expression of PD-L1 in the present study. Conclusions: In our study, PD-L1 immunopositivity was found in 40% of patients and majority of them exhibi

关键词： Lung Cancer PD-L1 IHC Biomarker Immunotherapy